Treatment of tuberculosis: Present status and future prospects

Bulletin of the World Health Organization

Volumn 83, Issue 11, 2005, Pages 857-865

  Onyebujoh, Philip ^a   Zumla, Alimuddin ^b   Ribeiro, Isabella ^a   Rustomjee, Roxana ^c   Mwaba, Peter ^d   Gomes, Melba ^a   Grange, John M ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^d UNIVERSITY OF ZAMBIA   (Zambia)

Author keywords

Antitubercular agents administration and dosage adverse effects; Directly observed therapy; Drug combinations; Drug therapy trends; Nitroimidazoles; Quinoline; Quinolizines; Quinolones; Tuberculosis, Multidrug resistant drug therapy

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; AMOXICILLIN; ANTIRETROVIRUS AGENT; AZITHROMYCIN; BETA LACTAMASE INHIBITOR; CAPREOMYCIN; CEFAZOLIN; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; CYCLOSERINE; CYTOCHROME P450; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KRQ 10018; LL 3858; MACROLIDE; MOXIFLOXACIN; NITROIMIDAZOLE DERIVATIVE; OFLOXACIN; PENICILLIN DERIVATIVE; PROTIONAMIDE; PYRAZINAMIDE; PYRIDOXINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLIZINE DERIVATIVE; RIFAMPICIN; RIFAMYCIN; SQ 109; STREPTOMYCIN; SULBACTAM; THIOACETAZONE; UNCLASSIFIED DRUG;

DISEASE CONTROL; DRUG PRESCRIBING; HUMAN IMMUNODEFICIENCY VIRUS; TUBERCULOSIS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; CONFUSION; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIRECTLY OBSERVED THERAPY; DIZZINESS; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FLU LIKE SYNDROME; HEADACHE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEUROTOXICITY; NONHUMAN; PATIENT COMPLIANCE; PREVALENCE; REVIEW; SKIN ALLERGY; SPUTUM SMEAR; STEVENS JOHNSON SYNDROME; STOMACH INJURY; TREATMENT FAILURE; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; CLINICAL PROTOCOLS; HIV INFECTIONS; HUMANS; PUBLIC HEALTH; TUBERCULOSIS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 27744545571     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Zumla A, Malon P, Henderson J, Grange JM. The impact of the human immunodeficiency virus (HIV) infection epidemic on tuberculosis. Postgrad Med J 2000 May;76(895):259-68.
2. Elzinga, G. Raviglione, M.C., Maher, D. Scale up: meeting targets in global tuberculosis control. Lancet 2004 Mar 6;363(9411):814-19.
3. An expanded DOTS framework for effective tuberculosis control. Geneva: World Health Organization; 2002.
4. Maher D, Floyd K, Raviglione M. A strategic framework to decrease the burden of TB/HIV. Geneva: World Health Organization; 2002.
5. Mitchison DA. The role of individual drugs in the chemotherapy of tuberculosis, Int J Tuberc Lung Dis. 2000 Sep;4(9):796-806.
6. Treatment of tuberculosis: guidelines for national programmes. 3rd ed. Geneva: World Health Organization; 2003.
7. World Health Organization/International Union Against Tuberculosis and Lung Disease. Anti-tuberculosis drug resistance in the world. Report No. 3. Geneva: World Health Organization; 2004. Available from: URL:www.who.int/ gtb/publications/drugresistance/2004/drs_report_1.pdf
8. Narayanan PR. Low rate of emergence of drug resistance in sputum positive patients treated with short course chemotherapy, Int J Tuberc Lung Dis 2001 Jan;5(1):40-5.
9. Mukherjee JS, Rich ML, Socci AR, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004 Feb 7;363(9407): 474-81.
10. Dincer I. Ergin A, Kocagoz T. The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis, Int J Antimicrob Agents 2004 Apr;23(4):408-11.
11. Farmer P, Kim JY. Community based approaches to the control of multidrug resistant tuberculosis: Introducing "DOTS-Plus". BMJ 1998 Sep 5;317(7159): 671-4.
12. Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug resistant tuberculosis (MDR-TB). Geneva: World Health Organization; 2000.
13. Frequently asked questions about the four-drug fixed-dose combination tablet recommended by the World Health Organization for treating tuberculosis. Geneva: World Health Organization; 2002. (WHO/CDS/STB/2002.18).
14. Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four-drug fixed dose combination with separate formulations at the same dose levels, Int J Pharm 2004 May 19;276(1-2):41-9.
15. Kumaresan J, Smith I, Arnold V, Evans P. Global TB drug facility: innovative global procurement, Int J Tuberc Lung Dis 2004 Jan;8(1):130-8.
16. Grange JM, Zumla A. Antituberculosis agents. In: Cohen J, Powderly WG, editors. Infectious diseases, 2nd ed. London: Elsevier Health Sciences; 2003. Section 7, p. 1851-67.
17. Grange JM. Antimycobacterial agents. In: Finch RG, Greenwood D, Norrby SR, Whitley RJ, editors. Antibiotic and chemotherapy. 8th ed. Edinburgh: Churchill Livingstone; 2003. p. 426-40.
18. Peloquin CA. Clinical pharmacology of the antituberculosis drugs. In: Davies PDO, editor. Clinical Tuberculosis. 3rd ed. London: Arnold; 2003. p. 171-90.
19. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003 Jun 1;167(11):1472-7.
20. Mitchell I, Wendon J, Fitt S, Williams R. Antituberculosis therapy and acute liver failure. Lancet 1995 Mar 4;345(8949):555-6.
21. Piscitelli SC, Gallicano PD, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001 Mar 29;344(13):984-96.
22. Yew WW. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf 2002;25(2):111 -33.
23. Centers for Disease Control and Prevention (CDC). Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Morb Mortal Wkly Rep 1998; 47(RR20): 1-51. Available from: URL:http://www.cdc.gov/ epo/mmwr/preview/mmwrhtml/00055357.htm
24. The economics of TB drug development. New York: Global Alliance for TB Drug Development; 2001.
25. Duncan K, Barry, CE. Prospects for new antitubercular drugs. Curr Opin Microbiol 2004 Oct;7(5):460-5.
26. Sharma K, Chopra P, Singh Y. Recent advances towards identification of new drug targets for Mycobacterium tuberculosis. Expert Opin Ther Targets 2004 Apr;8(2):79-93.
27. Tomioka H. Prospects for development of new antimycobacterial drugs. Infect Chemother 2000 Mar;6(1):8-20.
28. Andries K, Verhasselt P, Guillemont J et al. A diarlyquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005 Jan 14;307(5707):223-7.
29. Hampton T. TB drug research picks up the pace. JAMA 2005 Jun 8;293(22): 2705-7.
30. 2003/04 Annual Report. New York: Global Alliance for TB Drug Development; 2004. Available from: URL: http://www.tballiance.org
31. Tortoli E, Dionisio D, Fabbri C. Evaluation of moxifloxacin activity in vitro against Mycobacterium tuberculosis, including resistant and multidrug-resistant strains. J Chemother 2004 Aug;16(4):334-6.
32. Vangapandu S, Jain M, Jain R, Kaur S, Pal Singh P. Ring-substituted quinolines as potential anti-tuberculosis agents. Bioorg Med Chem 2004 May 15;12(10):2501-8.
33. Tuberculosis Research Centre (Indian Council of Medical Research), Chennai. Shortening short course chemotherapy: a randomised clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase, Ind J Tub 2002;49:27-38.
34. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998 Aug;42(8):2066-9.
35. Lalande V, Truffot-Pernot C, Paccaly-Moulin A, Grosset J, Ji. B. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice.Antimicrob Agents Chemother 1993 Mar;37(3):407-13.
36. Sirgel FA, Donald PR, Odhiambo J, Githui W, Umapathy KC, Paramasivan CN, et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 2000 Jun;45(6):859-70.
37. Cynamon MH, Sklaney M. Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob Agents Chemother 2003 Aug;47(8): 2442-4.
38. Bock NN, Sterling TR, Hamilton CD, Pachucki C, Wang YC, Conwell DS, et al. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med 2002 Jun 1;165(11): 1526-30.
39. Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O'Brien RJ, Vernon A, et al. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001 Dec;45(12):3482-6.
40. Dietze R, Teixeira L, Rocha LM, Palaci M, Johnson JL, Wells C, et al. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob Agents Chemother 2001 Jul;45(7):1972-6.
41. Barry CE 3rd, Boshoff HI, Dowd CS. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr Pharm Des 2004;10(26):3239-62.
42. Jia L, Tomaszewski JE, Hanrahan C, Coward L, Noker P, Gorman G, et al. Pharmacodynamics and pharmacokinetics of SQ 109, a new diamine-based antitubercular drug. Br J Pharmacol 2005 Jan;144(1):80-7.
43. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons (Cochrane Review). In: The Cochrane Library, Oxford: Update Software; 2003.
44. Peloquin CA, Nitta AT, Burman WJ, Brudney KF, Miranda-Massari JR, McGuinness ME, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996 Sep;30(9):919-25.
45. Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000 May 11;342(19):1416-29.
46. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. (Cochrane Review). In: The Cochrane Library, Oxford: Update Software; 2004.
47. Brewer TF, Heymann SJ. To control and beyond: moving towards eliminating the global tuberculosis threat. Epidemiol Community Health 2004 Oct;58(10): 822-5.
48. Kenyon TA, Mwasekagu MU, Huebner R. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. Int J Tuberc Lung Dis 1999 Jan;3(1):4-11.
49. Iseman MD. Tuberculosis therapy: past, present and future. Eur Respir J 2002;20:Suppl.36,87S-94S.